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Only a limited number of patients with amyloidosis and
pulmonary hypertension have been reported in the
literature. We report a 73-year-old female with AL type
amyloidosis who developed respiratory insufficiency and
right heart failure because of severe pulmonary hyper-
tension. There were no signs of cardiac involvement with
amyloid or findings consistent with interstitial lung
disease. Previous reports of pulmonary hypertension
without an apparent parenchymal lung or myocardial
involvement with amyloidosis are summarized. Pulmo-
nary hypertension due to deposition of amyloid in the
pulmonary vasculature is an uncommon finding; how-
ever, it should be considered in cases of unexplained
pulmonary hypertension in patients with amyloidosis.
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INTRODUCTION
Amyloidosis is the term for diseases that share a common
feature of extracellular deposition of pathologic insoluble
fibrillar proteins in organs and tissues.
1 The classification of
amyloidosis is based on the nature of precursor plasma
proteins that form the fibril deposits.
2 The most common form
is primary amyloidosis, also known as light chain amyloidosis.
The structural subunits of amyloid proteins in light chain (AL)
amyloidosis are made up of fragments of monoclonal immu-
noglobulin heavy chains or light chains.
3 The extracellular
deposits interfere with organ function and may lead to
premature death. The most common presentations are unex-
plained nephrotic syndrome, cardiomyopathy, hepatomegaly,
and peripheral neuropathy.
4 Clinically significant pulmonary
amyloidosis is uncommon despite the fact that amyloid
deposition in the lung parenchyma is a common histological
finding in this condition.
6 Isolated amyloid deposition in the
pulmonary vasculature, without clinically significant paren-
chymal involvement, is a histological finding that occurs to
some extent in all systemic forms.
7 However, pulmonary
hypertension is rarely reported in these cases.
The subject of this report is a patient with amyloidosis AL
type who presented with severe pulmonary hypertension
without an apparent cardiac or parenchymal lung involve-
ment. Previous reports of pulmonary hypertension in amyloid-
osis are summarized and discussed.
CASE REPORT
A 73-year-old woman presented with a 2-month history of
progressive exertional dyspnea, increasing leg edema, and
abdominal distention. Three days earlier, purpuric lesions
appeared spontaneously around her eyes. She reported no
chest pain, orthopnea, or paroxysmal nocturnal dyspnea.
Two years before admission, the patient presented with
symptomatic anemia and was diagnosed as having AL type
amyloidosis. Echocardiography and pulmonary function test
were not performed at that time. She received 1 course of
chemotherapy with prednisone and chlorambucil, which were
stopped because of severe pancytopenia without any addi-
tional chemotherapeutic treatments thereafter. The patient did
not have any other significant medical condition.
At presentation, the patient was tachypneic (respiratory rate
of 25/minute) and tachycardic (120 beats/minute). Her blood
pressure was 110/70 mmHg. Easily detectable purpuric rash
was noted around her eyes. Elevated jugular venous pressure
of 11 cm, prominent ascites, and leg edema grade 3 were also
noted. Auscultation of the heart revealed an accentuated
pulmonic component of the second heart sound and a grade
3/6 systolic murmur over the left sternal border. Inspiratory
rales were detected at the lower third of both lung fields. The
rest of the physical examination was unremarkable. Arterial
blood gas analysis on room air revealed a PO2 of 58 mmHg,
PCO2 of 30 mmHg, and pH=7.5.
Further laboratory workup revealed normocytic anemia
(Hb=10 gr/dL), thrombocytopenia of 60,000/mm
3, white blood
cells (WBC) of 9,500/mm
3, mild impairment of renal functions
(creatinine=1.1 mg/dL, urea=60 mg/dL), albumin=3.5 gr/dL,
globulin=3 gr/dL, hypercalcemia of 11.5 mg/dL, and a high
lactate dehydrogenase of 607 U/L (normal value <480 U/L).
Serum protein electrophoresis showed a 16.3 g/L monoclonal
spike in the gamma fraction and serum immunoelectrophoresis
demonstrated increased IgG level with monoclonal Lambda
chain peak. Urine test for Bence Johns proteins was positive.
Bone marrow biopsy confirmed adiagnosis ofmultiple myeloma
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416with plasma cells comprising 70% of the marrow elements.
Electrocardiogram showed sinus tachycardia with right bundle
branch block and prominent R waves in the right anterior leads
(V1–3).
Additional tests were ordered to investigate the respiratory
symptoms. A chest roentgenogram showed slightly increased
pulmonary markings. A transthoracic echocardiogram revealed
severe pulmonary hypertension with an estimated systolic
pulmonary arterial pressure of 90 mmHg and moderate tricus-
pid regurgitation, but good left ventricular function (ejection
fraction=66%). No signs of left to right shunt and no echocar-
diographic signs of restrictive cardiomyopathy or cardiac
amyloidosis were found.
Investigation of pulmonary hypertension was undertaken
and included ventilation–perfusion lung scan which revealed
nonhomogenous perfusion without segmental perfusion
defects that was interpreted as low probability of pulmonary
embolism. A high resolution computed tomography (CT) [high-
resolution computed tomography (HRCT)] angiogram of the
chest did not demonstrate evidence of pulmonary embolism or
signs of interstitial or other lung diseases. Lung functions are
summarized in Table 2 and were interpreted as normal
spirometry with decreased diffusing capacity of the lung for
carbon monoxide (DLCO). Serologic testing for HIV was negative
and no clinical findings or laboratory markers suggesting
collagen vascular disease were detected. Doppler ultrasound
of the portal vein and liver scan did not show signs of portal
hypertension or chronic liver disease. The patient refused
catheterization of the right heart. Based on the absence of
significant pulmonary parenchymal lung findings in HRCT, and
findings in pulmonary function tests that are consistent with
pulmonary hypertension, and the risk of lung biopsy in severe
pulmonary hypertension, we decided to avoid this procedure.
In light of the patient’s refusal to undergo right heart
catheterization, the diagnosis of pulmonary hypertension was
based on echocardiographic findings. Because of the absence
of a secondary condition causing pulmonary hypertension, the
most likely cause was deposition of amyloid in the pulmonary
vasculature. It should be noted, however, that this was merely
a diagnosis of exclusion. The patient was treated with nifedi-
pine and diuretics with subsequent clinical improvement in
signs and symptoms of right heart failure and slight lowering
of the pulmonary hypertension, with an estimated pulmonary
artery pressure of 84 mmHg in echocardiogram. She was
discharged with supplemental oxygen treatment. During the
subsequent 4 months, she received 10 additional courses of
prednisone and chlorambucil which were replaced by dexa-
methasone and cyclophosphamide. However, the respiratory
condition continued to deteriorate.
Six months after the first admission, the patient presented
with worsening dyspnea, cough, and leg edema. Chest roent-
genogram revealed an infiltrate in the left lower lung. Based on
a presumptive diagnosis of pneumonia, treatment with anti-
biotics, supplemental oxygen and diuretics were initiated. She
died because of progressive respiratory failure refractory to
treatment and died on the seventh hospital day. A postmortem
examination was declined by her family.
DISCUSSION
Only 8 cases of amyloidosis with pulmonary hypertension have
thus far been reported. We present a case of AL type
amyloidosis in association with severe pulmonary hyperten-
sion, which raises two issues: the relationship of pulmonary
hypertension to pulmonary amyloidosis and the role of amyloid
deposition and vascular dysfunctions.
Systemic light-chain deposition due to plasma cell dyscra-
sias usually causes restrictive cardiomyopathy due to cardiac
amyloidosis and manifests by signs and symptoms of diastolic
ventricular dysfunction. Restrictive cardiomyopathy can be
difficult to detect. Doppler evaluation of ventricular function is
essential to rule out cardiac amyloidosis and the absence of
characteristic findings of cardiac amyloidosis in echocardiog-
raphy, as in the present case, has a negative predictive value of
88%.
5 Hence, the possibility of cardiac amyloidosis as a main
cause of right heart failure in this case is low.
Pulmonary amyloidosis rarely causes symptoms despite the
fact that it is commonly found in autopsy.
6 Various classifica-
tionsofpulmonaryamyloidosishavebeenproposedbasedupon
the site of amyloid deposition. It is classified as tracheobron-
chial or parenchymal, the latter being further classified radio-
graphically either as solitary/multiple nodules or as a diffuse
Table 1. Features of Patients with Pulmonary Hypertension and Amyloidosis
Age Sex Type of
pulmonary
amyloidosis*
Cardiac
amyloidosis
†
Symptoms Type Age at
diagnosis of
amyloidosis
Age at
diagnosis
of PHTN
Estimated
PAP
(mmHg)
Multiple
Myeloma
Time to
death
(d)
1 91 F Alveolar
septal
NH F A L 9 1 9 1 – N
2 65 F Partial
alveolar
septal
N D, HF AL 65 65.5 39 Y 41
36 1 F – N D, HF AL 61 66.5 58 Y 19
46 4 F – ND , H F A L 6 4 6 4 – Y 892
58 2 M – ND , H F A L 8 2 8 2 – N 1,036
6 54 F Alveolar
septal
ND , H F A L 5 4 5 4 4 8 N 7 3
74 8 F – N D, CP, HF AA–FMF 48 48 62 N 61
8 Ab2M N
Current
case-9
73 F – N D, HF Al 71 73 90 Y 240
CP Chest pain, D dyspnea, HF heart failure, N no, PHTN pulmonary hypertension, Y yes.
*Diagnosis was made by lung biopsy or by autopsy in cases 1–2, 6–7.
†Cardiac amyloidosis was ruled out by echocardiography in cases 2–5 and 9 and by autopsy histological examination in cases 1, 6, and 7.
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6,7 Amyloid involvement of the pulmo-
nary vasculature is a histological finding that occurs at least, to
some extent, in all systemic forms
8; however, pulmonary
hypertension is only rarely reported.
Pulmonary arterial hypertension is defined as sustained
elevation of the pulmonary arterial pressure to more than
25 mmHg at rest or to more than 30 mmHg with exercise, with
left ventricular end-diastolic pressure of less than 15 mmHg.
9
Pulmonary arterial hypertension encompasses idiopathic pul-
monary hypertension, pulmonary arterial hypertension in the
setting of collagen vascular disease, portal hypertension,
congenital left-to-right intracardiac shunts, and infection with
human immunodeficiency virus (HIV).
10
Our patient was diagnosed as having multiple myeloma (MM)
with amyloidosis. The association between MM and pulmonary
hypertension has been rarely reported in the literature. All
reported cases were related to thalidomide treatment,
11–13
which is irrelevant to our case. As mentioned previously, de-
position of amyloid in the pulmonary vasculature is a common
histological finding. Amyloid deposition in blood vessel walls
can result in endothelial dysfunction and eventually lead to
pulmonary arterial hypertension. The pathologic mechanisms
that cause pulmonary arterial hypertension probably involve
vasoconstriction, smooth muscle cell and endothelial cell
proliferation, and thrombosis. This suggests the presence of
perturbations in the normal relationships between vasodilators
and vasoconstrictors, growth inhibitors and mitogenic factors,
and antithrombotic and prothrombotic determinants. These
homeostatic imbalances are probably consequences of pulmo-
nary endothelial cell dysfunction or injury.
14
Vasculopathy secondary to amyloid deposition can result in
flow abnormalities and ischemia. Vascular involvement has
been described in 88–90% of patients with AL amyloidosis.
15,16
Despite the frequent histological vascular involvement, clinical
expression secondary to amyloid vasculopathy is infrequent.
Suwaidi et al. described an abnormal response of endothelial-
dependent vasodilatation in the coronary arteries to acetyl-
choline infusion in patients with amyloidosis.
17 In addition,
β2-amyloid was shown to enhance the vasoconstriction in-
duced in aortic rings by phenylephrine and endothelin.
18
Hence, amyloid deposition in blood vessel walls can result in
systemic endothelial dysfunction. It is possible that similar
mechanisms operate in the pulmonary circulation causing
pulmonary hypertension. To the best of our knowledge, data
that support this suggestion are unavailable.
Until now, 8 patients with pulmonary hypertension and
amyloidosis without cardiac or parenchymal lung involvement
have been reported in the literature.
19–23 The main clinical and
laboratory findings in these reports and those of our patient are
summarized in Table 1.T h ed e t a i l so fo n ec a s ew i t hβ2
microglobulin amyloidosis
23 could not be obtained. The median
age of the patients at diagnosis of amyloidosis was 67±13, while
the median age at the diagnosis of pulmonary hypertension was
1 year higher (68 ± 13). All patients had exertional dyspnea and
signs of right heart failure upon physical examination. Seven
patients had AL amyloidosis, 1 patient had AA type amyloidosis
secondary to untreated familial Mediterranean fever, and 1
patient had β2 microglobulin amyloidosis secondary to hemo-
dialysis treatment. From the available echocardiographic data
(6 out of 9 patients), no evidence of cardiac amyloidosis was
found. The median left ventricular ejection fraction was 66%,
while all patients had right ventricular dilatation with de-
pressed function. Four patients underwent invasive pulmonary
artery pressure (PAP) measurements. The mean PAP was
51 mmHg. The diagnosis of pulmonary hypertension second-
ary to deposition of amyloid in the pulmonary vasculature was
confirmed by a lung biopsy in 5 cases. Follow-up data shows
rapid clinical deterioration in most of the patients, with a
median time until death of 73 days after the diagnosis of
pulmonary hypertension. In comparison, the mean survival of
patients with primary pulmonary hypertension without thera-
py is 2–3 years,
24 while that of patients with AL amyloidosis is
12 months.
1
In summary, we present a woman with amyloidosis who
developed dyspnea and right heart failure and was diagnosed
with pulmonary hypertension, most probably secondary to
pulmonary vascular involvement by amyloid fibrils. Dyspnea
and right heart failure are not uncommon in patients with
amyloidosis and are usually the consequence of cardiac and
pulmonary amyloidosis. Pulmonary hypertension due to
deposition of amyloid in the pulmonary vasculature is un-
common; nevertheless, it should be considered as a possibility
in unexplained pulmonary hypertension in patients with
amyloidosis.
Potential Financial Conflicts of Interest: None diclosed.
Corresponding Author: Lihi Eder, MD; Department of Internal
Medicine, Carmel Medical Center, Faculty of Medicine, Technion-
Israel Institute of Technology, 7 Michal St., Haifa 34362, Israel
(e-mail: ben@usha.org.il).
REFERENCE
1. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J
Med. 1997;337:898–909.
2. WHO-IUIS Nomenclature Sub-Committee. Nomenclature of amyloid and
amyloidosis. Bull World Health Organ. 1993;71:105–12.
3. Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenstrom’s
macroglobulinemia. Hematology. 2004;257–82.
4. Gertz MA, Lacy MQ, Dispenzieri A. Amyloidosis: recognition, confir-
mation, prognosis and therapy. Mayo Clin Proc. 1999;74:490–4.
5. Kalova I, Niessen H. Amyloid in the cardiovascular system: a review. J
Clin Pathol. 2005;58:125–33.
6. Utz JP, Swensen SJ, Gertz MA. Pulmonary amyloidosis: the Mayo Clinic
experience from 1980 to 1993. Ann Intern Med. 1996;124:407–13.
7. Thompson PJ, Citron KM. Amyloid and the lower respiratory tract.
Thorax. 1983;38:84–7.
8. Gilmore JD, Hawkins PN. Amyloidosis and the respiratory tract.
Thorax. 1999;54:444–51.
9. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med.
2004;351:1655–65.
10. Galie N, Manes A, Branzi A. Evaluation of pulmonary arterial hyper-
tension. Curr Opin Cardiol. 2004;19:575–81.
11. Antonioli E, Nozzoli C, Gianfaldoni G, Mannelli F, Rossi S, Betti S,
Bernardeschi P, Fiorentini G, Bosi A. Pulmonary hypertension related
to thalidomide therapy in refractory multiple myeloma. Ann Oncol.
2005;16:1849–50.
Table 2. Results of Pulmonary Function Tests
Actual Predicted Percent (%) Act/ Pre
FEV1 (L) 1.34 1.78 75.4
FVC (L) 1.68 2.17 77.6
FEV1/FVC (%) 79 75
DLCO 3.73 6.53 57.1
418 Eder et al.: Amyloidosis and Pulmonary Hypertension JGIM12. Hattori Y, Shimoda M, Okamoto S, Satoh T, Kakimoto T, Ikeda Y.
Pulmonary hypertension and thalidomide therapy in multiple myeloma.
Br J Haematol. 2003;121:191–2.
13. Younis TH, Alam A, Paplham P, Spangenthal E, McCarthy P.
Reversible pulmonary hypertension and thalidomide therapy for multi-
ple myeloma. Br J Haematol. 2003;123:563.
14. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX.
Cellular and molecular mechanisms of pulmonary vascular remodeling:
role in the development of pulmonary hypertension. Microvasc Res.
2004;68:75–103.
15. Crotty TB, Li CY, Edwards WD, Suman VJ. Amyloidosis and
endomyocardial biopsy: correlation of extent and patterns of deposition
with amyloid immunophenotype in 100 cases. Cardiovasc Pathol.
1994;5:39–42.
16. Smith TJ, Kyle RA, Lie JT. Clinical significance of histopathologic
patterns of cardiac amyloidosis. Mayo Clin Proc. 1984;59:547–55.
17. Suwaidi JA, Velianou JL, Gertz MA, Cannon RO, Higano ST, Holmes
DR. Systemic amyloidosis presenting with angina pectoris. Ann Int Med.
1999;131:838–41.
18. Crawford F, Suo Z, Frang C, et al. Characteristics of the in vitro
vasoactivity of beta-amyloid peptides. Exp Neurol. 1998;150:159–68.
19. Chapman AD, Brown PA, Kerr KM. Right heart failure as the dominant
clinical picture in a case of primary amyloidosis affecting the pulmonary
vasculature. Scott Med J. 1999;44:116–17.
20. Shiue ST, McNally DP. Pulmonary hypertension from prominent
vascular involvement in diffuse amyloidosis. Arch Int Med. 1988;148:
687–89.
21. Dingli D, Utz JP, Gertz MA. Pulmonary hypertension in patients with
amyloidosis. Chest. 2001;120:1735–8.
22. Johnson WJ, Lie JT. Pulmonary hypertension and familial Mediterra-
nean fever: a previously unrecognized association. Mayo Clin Proc. 1991;
66:919–25.
23. Lutz AE, Scneider U, Ehlerding G, Frenzel H, Koch KM, Kuhn K.
Right ventricular cardiac failure and pulmonary hypertension in a long-
term dialysis patient—unusual presentation of visceral beta 2-micro-
globulin amyloidosis. Nephrol Dial Transplant. 1995;10:555.
24. McLaughlin WV, Shillington A. Survival in primary pulmonary hyper-
tension: the impact of epoprostenol therapy. Circulation. 2002;106:1477.
419 Eder et al.: Amyloidosis and Pulmonary Hypertension JGIM